Results 91 to 100 of about 47,712 (207)

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration

Biomolecules
Glucagon-like peptide-1 (GLP-1)-based drugs have been approved by the United States Food and Drug Administration (FDA) and are widely used to treat type 2 diabetes mellitus (T2DM) and obesity.
Katherine O. Kopp, Yazhou Li, Elliot J. Glotfelty, David Tweedie, Nigel H. Greig   +4 more
doaj   +1 more source

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

Journal of Pharmacy & Pharmaceutical Sciences
Excess adiposity can contribute to metabolic complications, such as type 2 diabetes mellitus (T2DM), which poses a significant global health burden.
Arianne Morissette, Erin E. Mulvihill, Erin E. Mulvihill   +2 more
doaj   +1 more source

GLP-1 receptor agonists

, 2020
The evolution and discovery of a molecule derived from the proglucagon with incretinic effect is described. In the search for a molecule resistant to the rapid metabolism caused by DPP-4, it was found molecules such as Exendin 4 and subsequently the synthetic ones, specific to the GLP-1 receptor and resistant to the metabolism of DPP-4.
openaire   +1 more source

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties

Medicina
As an incretin hormone, Glucagon-like peptide-1 (GLP-1) has obvious effects on blood glucose regulation and weight loss. GLP-1 receptor (GLP-1R) agonists are synthetic products that have similar effects to GLP-1 but are less prone to degradation, and ...
Chenqi Lu, Cong Xu, Jun Yang
doaj   +1 more source

The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review

Drug Design, Development and Therapy
Zhao Liu,1 Shanshan Yu,1 Xinyan Jin,1 Luguang Sheng,2 Mai Re YanMu,1 Jie Gao,1 Jun Lu,1 Tao Lei1 1Department of Endocrinology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 2Department of ...
Liu Z, Yu S, Jin X, Sheng L, YanMu MR, Gao J, Lu J, Lei T   +7 more
doaj  

GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats

Endocrine Connections
Objective: Combination therapies with gut hormone analogs represent promising treatment strategies for obesity. This pilot study investigates the therapeutic potential of modulators of the glucagon-like peptide 1 (GLP-1) and neuropeptide Y (NPY) system ...
Marie Oertel, Christian G Ziegler, Michael Kohlhaas, Alexander Nickel, Simon Kloock, Christoph Maack, Vasco Sequeira, Martin Fassnacht, Ulrich Dischinger   +8 more
doaj   +1 more source

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants

Frontiers in Pharmacology
BackgroundObesity is a chronic inflammatory disease with high morbidity that is decidedly prevalent worldwide and in Saudi Arabia. Glucagon-like peptide 1 receptor agonists (GLP-1 agonists) are broadly used for the management of diabetes and obesity.
Amirah Alhowiti, Hyder Mirghani, Abdulaziz Abdulrahman Qrmli, Amal Abdullah Albalawi, Raneem Abdulrahman Aljohani   +4 more
doaj   +1 more source

Integrating the inputs that shape pancreatic islet hormone release. [PDF]

, 2019
The pancreatic islet is a complex mini organ composed of a variety of endocrine cells and their support cells, which together tightly control blood glucose homeostasis.
Huising, Mark O, Noguchi, Glyn M
core  

Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials

BMC Endocrine Disorders
Objective To evaluate the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obesity among children and adolescents.
Qirong Chen, Haixia Liu, Jie Xu, Yu Zhou, Junying Ma   +4 more
doaj   +1 more source

The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS

Quality in Sport
Introduction and aim of study: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting young women. It is diagnosed in individuals who meet 2 of the following 3 criteria: hyperandrogenism, ovarian dysfunction or ...
Aleksandra Jaroń, Agata Wiklińska, Katarzyna Jastrzębska, Maria Witkowska, Joanna Skotnicka, Karolina Błaszczak, Monika Turek, Klara Wojciechowska, Adrian Borkowski, Mateusz Sawicki   +9 more
doaj   +1 more source